



Biosurveillance in a Global Age: Harnessing the Expertise of the Broad Scientific Community




TECHNOLOGY DRIVEN. WARFIGHTER FOCUSED.


NDIA Biosurveillance Conference


Dr. C. Nicole Rosenzweig

US Army, Edgewood Chemical Biological Center

27 August 2012












- Biosafety Level 3 laboratory for growing CDC category A and B select-agents
- Sequencing facility with the capacity to support of genomics and transcriptomics research
- BSL 2 and BSL 3 bio-aerosol research for challenging equipment and developing risk assessments
- Contemporary molecular biology, microbiology and biochemistry techniques
- Roche, Illumina, Opgen Argus platforms
- Sample processing experience with medical, environmental, and cultured material


Whole-genome sequencing ID's Mutations



Strain Origins & History Revealed by WGS




GENOMIC ANALYSIS



MBL's are β -lactamase enzymes that can destroy virtually all β -lactam based Antibiotics Penicillins, cephalosporins and carbapenems

Antibiotic	MIC (mg/L)			% susceptible ^a
	Range	MIC ₅₀	MIC ₉₀	
Imipenem	8 - >128	32	128	0%
Imipenem + EDTA	0.125 - 8	0.25	1.2	n/a
Meropenem	2 - >32	32	32	3%
Ertapenem	2 - >16	16	16	0%
Ampicillin	>64	>64	>64	0%
Piperacillin	>64	>64	>64	0%
Piperacillin-tazobactam	32 - >64	>64	>64	0%
Cefotaxime	128 - >256	>256	>256	0%
Ceftazidime	64 - >256	>256	>256	0%
Cefpirome	>64	>64	>64	0%
Aztreonam	0.125 - >64	>64	>64	11%
Ciprofloxacin	0.125 - >8	>8	>8	8%
Gentamicin	0.5 - >32	>32	>32	3%
Tobramycin	8 - >32	>32	>32	0%
Amikacin	16 - >64	>64	>64	0%
Minocycline	2 - >32	16	>32	0%
Tigecycline	0.25 - 8	1	4	64%
Colistin	0.5 - >32	0.5	8	89% ^b



Mark Toleman, Cardiff University


TECHNOLOGY DRIVEN. WARFIGHTER FOCUSED.

- *Yersinia pestis* KIM
- Constructed in 1990's in U.S.A. to facilitate pCD1 virulence plasmid transfer between strains
- Contains ampicillin resistance marker

Iteration	De novo contigs (Median Depth)	Total Assembled Bases	Identified Reference	RefSeq Accession	# Reads Mapped	% Ref coverage
1	205 (44)	4586247	YP KIM Chromosome	NC_004088.1	555517	98.64
2	14 (76)	169035	YP KIM pCD1	NC_004836.1	29312	95.92
3	6 (66)	104051	YP KIM pMT1	NC_004838.1	16076	95.43
4	2 (23)	8844	<i>E. coli</i> A2363 plasmid pAPEC-02-R	NC_006671.1	368	1.0
5	1 (22)	7616	YP KIM pPCP1	NC_004837.1	442	90.95


Thursday, March 03, 2011 3:59 PM
Project: Untitled.sqd Contig 1

Page 1



TEM-1 β -lactamase

ECBC Is Involved in Active Biosurveillance Programs



Long term: use best of breed analytics to improve analysis

Short term: identify capabilities that provide high-value analysis



Amazon Cloud

Web Services
Communication
Analysis Requests
Data Exchange

DoD Firewall

ECBC HPC



Amazon Cloud


Web Services
Communication
Analysis Requests
Data Exchange

DoD Firewall

ECBC HPC



2-Tiered System



Amazon Cloud

Web Services
Communication
Analysis Requests

Data Packet

DoD Firewall

ECBC HPC



Amazon Cloud

Web Services
Communication
Analysis

DoD Firewall

ECBC HPC




Data Packet

Forum - pathosphere.org

C. Nicole Rosenzweig (Sign Out)

Everything



GLOBAL PATHWAY FOR DISCOVERY

- Welcome
- Guide
- Communities
- Analysis
 - File Manager
 - Pathogen Detection
 - Cross Sample ID
- Columbia-CII
 - Forum
- Luminex
- Contig Program
 - Forum
- Decision Support Team
 - Forum
 - Documents
- ECBC-GS
 - Forum
 - FOUO Database
 - Documents
- Pathosphere Team
 - Forum
 - Wiki
 - Documents
- TRI Collaborations
 - Forum

TRI Message Board

Message Boards Home | Recent Posts | My Posts | My Subscriptions | Statistics | Banned Users

Add Category | Post New Thread | Permissions

RSS (Opens New Window) | Unsubscribe

Categories

Category	Categories	Threads	Posts	
MiSeq Data Set 1 - Clinical Isolates Subcategories: Combined Assembly Discussion , Roche Junior Data from 2011	2	9	16	Actions
MiSeq Data Set 2 - Clinical Samples Subcategories: Sample Information	1	3	18	Actions
MiSeq Data Set 3 - Assay Confounders Isolates	0	2	20	Actions

Showing 3 results.

Threads


There are no threads in this category.

Settings | Online Friends (0)

Internet | Protected Mode: Off | 100%



- Where do biodetection capabilities need improvement?
- How can research efforts support reliable biodetection for biosurveillance?
- How can analytical and data security be maintained while creating a flexible informatics capability?

- Mechanism for DoD OCONUS facilities to share information between their personnel, regional hospitals, and US subject matter experts.
- Informatics resources should be developed in a way that provides a mechanism for analytical tool delivery in real time.
- Sequencing can be used for initial detection, but it is time consuming and expensive. Validation through traditional methods is required. Diagnosis completed by medical personnel.
- Decision makers make unambiguous decisions on ambiguous data. Scientific confidence must be communicated clearly.



DTRA ALGORITHM PRIZE

The Challenge: Given raw sequence read data from a complex diagnostic sample, what algorithm can most rapidly and accurately process the data? DTRA is sponsoring an open competition with **\$1M** in awards available to the team(s) that can **best characterize an unknown sample**, with the least computational overhead. Prize details and sequencing datasets will be made available this Fall. Monitor <http://www.dtra.mil/Business.aspx> for updates.



ECBC

Henry Gibbons
Stacey Broomall
Mohamed Aitichou
Mark Karavis
Joe Insalaco
Alvin Liem
Jessica Hill
Michael Krepps
Pierce Roth
Eddie Salinas
Ed Megan
Greg Donarum
Ed Fochler
Patrick Carcel
Josh Schulte

Columbia University

Ian Lipkin
David Hirschberg

TRI

Evan Skowronski
David Klinzing
Kent Kawashima

Funding provided by the Defense Threat Reduction Agency. Conclusions and opinions presented here are those of the authors and are not the official policy of the U.S. Army, ECBC or the U.S. Government.

**RESEARCH
& TECHNOLOGY**

ENGINEERING

**OPERATIONS
& INTEGRATION**

WARFIGHTER NEEDS

WARFIGHTER SOLUTIONS



LIFECYCLE CHEMICAL AND BIOLOGICAL SOLUTIONS

MISSION: Integrate lifecycle science, engineering and operations solutions to counter CB threats to U.S. forces and the nation.

VISION: To be the premier resource for Chemical, Biological, radiological, nuclear and Explosive (CB_{RN}E) solutions, uniting and informing the national defense community.

Basic research through technology development, engineering design, equipment evaluation, production support, sustainment, field operations and disposal.

TECHNOLOGY DRIVEN. WARFIGHTER FOCUSED.

Technology Driven Warfighter Focused

EDGEWOOD CHEMICAL BIOLOGICAL CENTER

For more information about the Edgewood Chemical Biological Center visit
www.ecbc.army.mil

[or email the Public Affairs Office](#)



UNCLASSIFIED